MODERNA INC. DL-,0001 WKN: A2N9D9 ISIN: US60770K1079 Kürzel: MRNA Forum: Aktien Thema: Hauptdiskussion

... manno. Wann entwickelt moderna mal was gegen Durchfall?

60€

121?

Wo ist der Boden von dit Ganze? 127? 121y

Interessantes Interview⬆️⬆️⬆️, finde ich. Unabhängig von der kurzfristigen Kursentwicklung wird man sich als Anleger hier in einigen Jahren wohl freuen dürfen. Und da es sich um eine Ami-Aktie handelt, wahrscheinlich überproportional.

https://m.bild.de/leben-wissen/moderna-chef-wir-wollen-alle-viren-ausrotten-666bd0edf0b83b5fdb6d09df?source=puerto-reco-2_bild-V10.3.B_Test

M. M. N. Wird es weiter korrigieren. Vor news steigen pharmas wie eh und je schon immer um danach wieder zu korrigieren. Bestes Beispiel nova. Ich schätze die 100 kommen nochmal wenn u. A. der nas dann mal richtig korrigiert

Wird es trotz der vielversprechenden news wohl weiter korrigieren? Will hier eigentlich ganz gerne aufstocken, bin derzeit aber hin- u hergerissen.

https://www.deraktionaer.de/artikel/deraktionaerplus/moderna-jetzt-geht-es-schlag-auf-schlag-20359470.html

Moderna announces Phase 3 trial of mRNA-1283 met primary efficacy endpoint Moderna announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax. The Company also announced that higher efficacy was observed in adults 18 years of age and older compared to Spikevax, with a consistent trend observed in the subset of adults age 65 and older. Positive interim immunogenicity results for mRNA-1283 in this study were previously reported in March 2024. The ongoing Phase 3 clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older. Half of the participants received a 10 undefined dose of mRNA-1283, while the other half received a 50 undefined dose of mRNA-1273. Today's vaccine efficacy data are consistent with the previously announced immunogenicity results from the study, which showed that mRNA-1283 had higher neutralizing antibody responses against both Omicron BA.4/5 and ancestral SARS-CoV-2 than mRNA-1273, with the highest geometric mean titer ratios observed in adults and in the subset of participants aged 65 years and older. In the trial, mRNA-1283 was found to have a similar safety profile to Spikevax. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia. Moderna's combination vaccine candidate against influenza and COVID-19, mRNA-1083, includes mRNA-1283. That vaccine candidate recently announced positive results in its separate Phase 3 trial. Moderna plans to present the Phase 3 clinical data for mRNA-1283 at an upcoming conference as well as submit it for publication. The Company will also engage with regulators on the next steps for the program.

Oppenheimer maintains Moderna MRNA at Outperform and raises the price target from $163 to $179

88 Energy wird bald durch die Decke gehen da sollte sich jeder paar holen.....88 Energy wird bald durch die Decke gehen da sollte sich jeder paar holen.....

Gute Daten für Modernas mRNA-Kombinationsimpfstoff https://www.pharmazeutische-zeitung.de/gute-daten-fuer-modernas-mrna-kombinationsimpfstoff-147935/ https://www.mdr.de/wissen/medizin-gesundheit/Moderna-Positive-Phase-drei-Ergebnisse-fuer-kombinierten-Grippe-Corona-Impfstoff-100.html

BANG!

$MRNA Moderna's mRNA-3705 selected by FDA for START pilot program Moderna announced that the U.S. Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia due to methylmalonic-CoA mutase deficiency. The START pilot program was initiated by the U.S. FDA in September 2023 to accelerate the development of novel treatments addressing unmet medical needs in rare diseases, with an initial selection of up to seven novel treatments, three by the Center for Drug Evaluation and Research and four by the Center for Biologics Evaluation and Research. The milestone-driven initiative is intended to help the progression to pivotal clinical studies or pre-BLA/NDA meeting stages by enhancing communications between manufacturers and the U.S. FDA. Selected manufacturers will benefit from rapid, ad-hoc U.S. FDA interactions to support clinical development, such as study design, patient population, and statistical methods, beyond standard formal meetings. The program is designed to generate high-quality, reliable data to support marketing approvals, ensuring promising treatments advance efficiently through regulatory milestones. mRNA-3705 is being investigated in a Phase 1/2 study, called the "Landmark study," an adaptive, open-label study designed to evaluate the safety and tolerability of the investigational therapeutic administered via intravenous infusion in patients one year and older with isolated MMA due to methylmalonyl-CoA mutase deficiency.